期刊文献+

长期生存率比较的统计检验法 被引量:2

下载PDF
导出
摘要 目的针对基于生存数据的长期疗效分析的问题,特别是两条生存曲线出现交叉或危险率不成比例的情况下,比较在特定时刻点后组间生存率的差异,本文主要介绍组合检验法ZOLS、ZSP,p和χ^2三种检验的适用情况。方法在两组危险率不满足比例风险假定的前提下,对生存曲线交叉和后期差异大的两个例子,分别使用ZOLS、ZSP,p和χ^2三种方法检验在不同时刻点之后组间生存率的差异。结果两个例子中,ZOLS检验与χ^2检验对不同时刻点之后的组间生存率差异进行检验,均能得出较为一致的结论,并且与实际情况符合。而ZSP,p检验的结果与前两种相比有差异。结论结合实例分析,在比较长期疗效或者生存曲线特定时间点后的生存率时,建议使用ZOLS检验与χ^2检验。
出处 《中国卫生统计》 CSCD 北大核心 2016年第3期534-536,共3页 Chinese Journal of Health Statistics
基金 国家自然科学基金(81202288) 广州市科技计划(2012J5100023) 广东省大学生创业创新训练计划(1212113039) 南方医科大学科研启蒙计划(B1012444)
  • 相关文献

参考文献8

  • 1Klein JP, Moeschberger ML. Survival Analysis:Techniques for Cen- sored and Truncated Data. Second Edition. New York: Springer, 2003.
  • 2Grambsch P, Therueau T. Proportional hazards tests and diagnostics based on weighted residuals. Biometrics, 1994,81 ( 3 ) : 515-526.
  • 3Li H, Han D, Hou Y, et al. Statistical Inference Methods for Two Crossing Survival Curves:A Comparison of Methods. PLoS ONE, 2015,10( 1 ) :e0116774.
  • 4李慧敏,韩栋,陈征,陈平雁,Nakamura Tsuyoshi.生存曲线交叉时统计推断方法的比较和选择[J].中国卫生统计,2013,30(5):668-672. 被引量:7
  • 5陈金宝,邱李斌,王北琪,曾洁,陈征.固定点处组间生存率比较的统计检验法[J].中华流行病学杂志,2015,36(2):186-188. 被引量:6
  • 6Logan BR, Klein JP, Zhang M. Comparing Treatments in the Presence of Crossing Survival Curves : An Application to Bone Marrow Trans- plantation. Biometrics ,2008,64 ( 3 ) :733-740.
  • 7Bresalier RS, Sandier RS, Quan H, et al. Cardiovascular Events Asso- ciated with Rofecoxib in a Colorectal Adenoma Chemoprevention Tri- al. N Engl J Med,2005,352( 11 ) :1092-1102.
  • 8Royston P ,Mahesh KBP. The use of restricted mean survival time to estimate the treatment effect in randomized clinical trials when the proportional hazards assumption is in doubt. Statistics in Medicine, 2011,30(19) :2409-2421.

二级参考文献19

  • 1项永兵,高玉堂,金凡,杨工,孙璐.生存率置信区间的五种估计方法[J].中华流行病学杂志,1995,16(5):306-309. 被引量:3
  • 2Gehan EA. A generalized wilcoxon test for comparing arbitrarily singly- censored samples. Biomewika, 1965,52(1-2) :203-223.
  • 3Tarone RE,Ware JH. On distribution-free tests for equality of survival distributions. Biometrika, 1977,64 ( 1 ): 156-160.
  • 4Klein JP, Moeschberger ML. Survival analysis. Second Edition. New York, Snrinuer,2003.
  • 5Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chem- otherapy as first-line treatment for European patients with advanced EG- FR mutation-positive non-small-cell lung cancer (EURTAC) :a multi- centre, open-label, randomised phase 3 trial. The Lancet Oncology, 2012,13 (3) :239-246.
  • 6Samandari T, Agizew TB, Nyirenda S, et al. 6-month versus 36-month isoniazid preventive treatment for tuberculosis in adults with HIV infec- tion in Botswana: a randomised, double-blind, placebo-controlled trial. The Lancet ,2011,377 (9777) : 1588-1598.
  • 7Gill RD. Censoring and stochastic integrals. Mathematical Centre Tracts. Amsterdam : Mathematisch Centrum, 1980 : 124.
  • 8Lin X, Wang HK. A new testing approach for comparing the overallhomogeneity of survival curves. Biometrical Journal ,2004,46 (5) :489- 496.
  • 9Qiu PH, Sheng J. A two-stage procedure for comparing hazard rate functions. Journal of the Royal Statistical Society Series B, 2008,70 (1) :191-208.
  • 10Burton A, Altman DG, Royston P, et al. The design of simulation stud- ies in medical statistics. Statistics in Medicine, 2006,25 ( 24 ) : 4279- 4292.

共引文献10

同被引文献5

引证文献2

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部